No Data
No Data
Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations
Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
Relief Therapeutics Signs Letter of Intent With Renexxion for Reverse Merger
Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment
Relief Gains as Experimental Therapy Performs on Par With BioMarin's Kuvan
Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024